A detailed history of Jpmorgan Chase & CO transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,884,730 shares of APLS stock, worth $129 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,884,730
Previous 3,177,470 22.26%
Holding current value
$129 Million
Previous $122 Million 8.08%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$28.84 - $41.15 $20.4 Million - $29.1 Million
707,260 Added 22.26%
3,884,730 $112 Million
Q2 2024

Aug 12, 2024

BUY
$38.07 - $59.71 $36.7 Million - $57.5 Million
963,161 Added 43.5%
3,177,470 $122 Million
Q1 2024

May 10, 2024

SELL
$55.39 - $72.47 $19.9 Million - $26.1 Million
-359,824 Reduced 13.98%
2,214,309 $130 Million
Q4 2023

Feb 12, 2024

BUY
$37.14 - $64.82 $13.2 Million - $23.1 Million
356,386 Added 16.07%
2,574,133 $154 Million
Q3 2023

Nov 14, 2023

BUY
$23.65 - $89.22 $10.2 Million - $38.4 Million
430,765 Added 24.11%
2,217,747 $84.4 Million
Q2 2023

Aug 11, 2023

BUY
$76.68 - $93.31 $10.6 Million - $12.9 Million
138,530 Added 8.4%
1,786,982 $163 Million
Q1 2023

May 18, 2023

BUY
$46.59 - $66.96 $5.79 Million - $8.33 Million
124,357 Added 8.16%
1,648,452 $109 Million
Q1 2023

May 11, 2023

SELL
$46.59 - $66.96 $15.1 Million - $21.6 Million
-323,214 Reduced 17.5%
1,524,095 $101 Million
Q4 2022

Feb 13, 2023

BUY
$43.24 - $61.04 $39.2 Million - $55.4 Million
907,262 Added 96.51%
1,847,309 $95.5 Million
Q3 2022

Nov 14, 2022

SELL
$44.76 - $69.66 $5.99 Million - $9.33 Million
-133,918 Reduced 12.47%
940,047 $64.2 Million
Q2 2022

Aug 11, 2022

SELL
$35.07 - $59.21 $6.74 Million - $11.4 Million
-192,273 Reduced 15.18%
1,073,965 $48.6 Million
Q1 2022

May 11, 2022

SELL
$35.46 - $54.12 $11.4 Million - $17.4 Million
-321,640 Reduced 20.26%
1,266,238 $64.3 Million
Q4 2021

Feb 10, 2022

BUY
$30.74 - $49.16 $1.68 Million - $2.69 Million
54,736 Added 3.57%
1,587,878 $75.1 Million
Q3 2021

Nov 12, 2021

BUY
$31.4 - $69.84 $48.1 Million - $107 Million
1,533,142 New
1,533,142 $50.5 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.65B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.